Michael Burkes Brophy Sells 1,238 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,238 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $93.14, for a total value of $115,307.32. Following the transaction, the chief financial officer now owns 69,408 shares in the company, valued at $6,464,661.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The shares were sold at an average price of $89.55, for a total value of $63,132.75.
• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total transaction of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total value of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total value of $1,509,092.13.

Natera Stock Up 1.4 %

Shares of NTRA opened at $94.15 on Thursday. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $98.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The business’s 50 day moving average price is $89.57 and its 200-day moving average price is $68.74.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. On average, equities analysts predict that Natera, Inc. will post -2.35 earnings per share for the current year.

Analyst Ratings Changes

NTRA has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their price objective on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research report on Friday, April 5th. The Goldman Sachs Group raised their price objective on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, April 15th. Craig Hallum began coverage on Natera in a report on Monday, April 8th. They set a “buy” rating and a $117.00 target price on the stock. Finally, Piper Sandler increased their target price on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.40.

Hedge Funds Weigh In On Natera

Hedge funds have recently bought and sold shares of the company. Norges Bank bought a new stake in Natera during the 4th quarter valued at about $83,970,000. American Century Companies Inc. grew its holdings in shares of Natera by 115.7% during the third quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company’s stock valued at $73,203,000 after buying an additional 887,409 shares during the last quarter. Invesco Ltd. increased its position in shares of Natera by 52.0% during the third quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock valued at $111,930,000 after acquiring an additional 865,404 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Natera by 289.7% during the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock valued at $53,258,000 after acquiring an additional 632,047 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Natera by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock worth $687,280,000 after acquiring an additional 588,147 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.